Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Prospective, Randomized, Active-Controlled, Open-Label, Phase III Study to Test the Non-Inferiority of Intravenous Injection of Ferric Bepectate IV Injection Compared to Ferric Carboxymaltose for Treatment of Patients With Iron Deficiency Anaemia (IDA)

NCT07687784 is registered in ClinicalTrials.gov with AFT Pharmaceuticals, Ltd. as lead sponsor.

NCT NCT07687784
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07687784 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Prospective, Randomized, Active-Controlled, Open-Label, Phase III Study to Test the Non-Inferiority of Intravenous Injection of Ferric Bepectate IV Injection Compared to Ferric Carboxymaltose for Treatment of Patients With Iron Deficiency Anaemia (IDA)
Lead sponsor
AFT Pharmaceuticals, Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
July 31, 2028
Enrollment
1,366 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

iron deficiency anemia (ida)